Table 2 Laboratory findings, prevalence of lipid disorder and treatments in both groups
Study Group | Young Age Group | Elderly Age Group | P | ||
|---|---|---|---|---|---|
Total Number (n) | 494 | 1657 | |||
Reported Lipid Disorder | 2.6% | 37.1% | <0.01 | ||
Laboratory findings | |||||
Total Cholesterol, median (IQR (interquartile range)), mmol/L | 4.5 (4.0 – 5.1) | 5.6 (4.9 – 6.3) | <0.01 | ||
LDL-Cholesterol, median (IQR), mmol/L | 2.5 (2.0 – 3.0) | 3.4 (2.8 – 4.0) | <0.01 | ||
HDL-Cholesterol, median (IQR),all, mmol/L | 1.5 (1.3 – 1.8) | 1.6 (1.3 – 1.9) | 0.097 | ||
HDL-Cholesterol, median (IQR), by sex, mmol/L | female 1.8 (1.5–2.0) | male 1.4 (1.1-1.6) | female 1.8 (1.5-2.0) | male 1.4 (1.1-1.7) | <0.01/<0.01 |
Lipoprotein(a), median (IQR), mg/dL | 7.0 (1.5 – 21.0) | 11.0 (4.6 – 33.9) | <0.01 | ||
Triglycerides, median (IQR), mmol/L | 0.9 (0.7 – 1.2) | 1.1 (0.9 – 1.5) | <0.01 | ||
Any measured Lipid Disorder | 40.6% | 76.0% | <0.01 | ||
- Hypercholesterolemia (Total Cholesterol >= 5.2 mmol/L) | 23.7% | 64.0% | <0.01 | ||
- Hypertriglyceridemia (Triglycerides >= 2.3 mmol/L) | 3.5% | 6.8% | <0.01 | ||
- Combined Hyperlipoproteinaemia (Total Cholesterol >= 5.2 mmol/L and Triglycerides >= 2.3 mmol/L) | 2.6% | 4.6% | 0.054 | ||
- Hyperlipoproteinemia(a) (lipoprotein(a) >= 50 mg/dL) | 7.9% | 18.3% | <0.01 | ||
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/L in women), all | 13.0% | 11.0% | 0.238 | ||
- Low HDL Cholesterol (HDL Cholesterol <1.0 mmol/L in men or <1.3 mmol/L in women), by sex | female 11.6% | male 14.5% | female 9.8% | male 12.3% | 0.342/0.107 |
- Combined Hypertriglyceridemia and Low HDL Cholesterol | 2.3% | 3.1% | 0.356 | ||
Consultation of a general practitioner during the last 3 months | 35.0% | 60.3% | <0.01 | ||
Treated with any lipid-lowering medication | 0.0% | 16.8% | <0.01 | ||
- Statins | 0.0% | 16.3% | <0.01 | ||
- Fibrates | 0.0% | 0.2% | 0.274 | ||
- Ezetimibe | 0.0% | 1.1% | 0.02 | ||
LDL-treated to target, ESC-Guidelines | 97.6% | 7.4% | <0.01 | ||